Morgan Stanley analyst Matthew Harrison raised the firm’s price target on Denali Therapeutics to $63 from $61 and keeps an Overweight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNLI:
- Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
- Denali Therapeutics to present DNL343 Phase 1b data at AAN annual meeting
- Denali Therapeutics price target lowered to $32 from $36 at Stifel
- Denali Therapeutics price target lowered to $70 from $85 at Oppenheimer
- Denali Therapeutics price target lowered to $50 from $80 at Evercore ISI
